

Patterned progression of gut microbiota associated with necrotizing enterocolitis and late onset sepsis in preterm infants: a prospective study in a Chinese neonatal intensive care unit

Jiayi Liu¹, Yuqing Li¹, Yi Feng¹, Liya Pan¹, Zhoulonglong Xie², Zhilong Yan², Li Zhang³, Mingkun Li^{3,4}, Jianhua Zhao⁵, Jianhua Sun^{Corresp., 6}, Li Hong^{Corresp., 1}

¹ Department of Clinical Nutrition, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University, Shanghai, China

² Department of Surgery, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University, Shanghai, China

³ Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, China Academy of Science, Beijing, China

⁴ Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming, China

⁵ Shanghai Majorbio Bio-pharm Technology Co., Ltd, Shanghai, China

⁶ Department of Neonatology, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University, Shanghai, China

Corresponding Authors: Jianhua Sun, Li Hong

Email address: sunjianhua@scmc.com.cn, hongli@scmc.com.cn

Necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) are two common premature birth complications with high morbidity and mortality. Recent studies in Europe and America have linked gut microbiota dysbiosis to their etiology. However, similar studies in Asian populations remain scant. In this pilot study, we profiled gut microbiota of 24 Chinese preterm infants from birth till death or discharge from NICU. Four of them developed NEC and three developed LOS. Unexpectedly, we detected highly-diversified microbiota with similar compositions in all patients shortly after birth. However, as patients aged, the microbial diversities in case groups differed significantly from that of the control group. These differences emerged after the third day of life and persisted throughout the course of both NEC and LOS. Using a Zero-Inflated Beta Regression Model with Random Effects (ZIBR), we detected higher *Bacillus* ($p = 0.032$) and *Solibacillus* ($p = 0.047$) before the onset of NEC and LOS. During NEC progression, *Enterococcus*, *Streptococcus* and *Peptoclostridium* were the dominant genera while during LOS progression; *Klebsiella* was the only dominant genus that was also detected by the diagnostic hemoculture. These results warrant further studies to identify causative microbial patterns and underlying mechanisms.

1 **Patterned progression of gut microbiota**
2 **associated with necrotizing enterocolitis**
3 **and late onset sepsis in preterm infants: a**
4 **prospective study in a Chinese neonatal**
5 **intensive care unit**

6 **Jiayi Liu¹, Yuqing Li¹, Yi Feng¹, Liya Pan¹, Zhoulonglong Xie², Zhilong**
7 **Yan², Li Zhang³, Mingkun Li^{3,4}, Jianhua Zhao⁵, Jianhua Sun⁶, and Li**
8 **Hong¹**

9 ¹**Department of Clinical Nutrition, Shanghai Children's Medical Center, School of**
10 **Medicine Shanghai Jiao Tong University, Shanghai, China**

11 ²**Department of Surgery, Shanghai Children's Medical Center, School of Medicine**
12 **Shanghai Jiao Tong University, Shanghai, China**

13 ³**Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics,**
14 **China Academy of Science, Beijing, China**

15 ⁴**Center for Excellence in Animal Evolution and Genetics, Chinese Academy of**
16 **Sciences, Kunming, China**

17 ⁵**Shanghai Majorbio Bio-Pharm Technology Co., Ltd, Shanghai, China**

18 ⁶**Department of Neonatology, Shanghai Children's Medical Center, School of Medicine**
19 **Shanghai Jiao Tong University, Shanghai, China**

20 Corresponding author:
21 Jianhua Sun, Li Hong

22 Email address: sunjianhua@scmc.com.cn, hongli@scmc.com.cn

23 **ABSTRACT**

24 Necrotizing enterocolitis (NEC) and late-onset sepsis(LOS) are two common premature birth complica-
25 tions with high morbidity and mortality. Recent studies in Europe and America have linked gut microbiota
26 dysbiosis to their etiology. However, similar studies in Asian populations remain scant. In this pilot study,
27 we profiled gut microbiota of 24 Chinese preterm infants from birth till death or discharge from NICU.
28 Four of them developed NEC and three developed LOS. Unexpectedly, we detected highly-diversified
29 microbiota with similar compositions in all patients shortly after birth. However, as patients aged, the
30 microbial diversities in case groups differed significantly from that of the control group. These differences
31 emerged after the third day of life and persisted throughout the course of both NEC and LOS. Using a
32 Zero-Inflated Beta Regression Model with Random Effects (ZIBR), we detected higher *Bacillus* ($p = 0.032$)
33 and *Solibacillus* ($p = 0.047$) before the onset of NEC and LOS. During NEC progression, *Enterococcus*,
34 *Streptococcus* and *Peptoclostridium* were the dominant genera while during LOS progression, *Klebsiella*
35 was the only dominant genus that was also detected by the diagnostic hemoculture. These results
36 warrant further studies to identify causative microbial patterns and underlying mechanisms.

37 **INTRODUCTION**

38 The gut microbiota is a crucial contributor to human health. Imbalance of the microbial community,
39 termed dysbiosis, is associated with various diseases, such as obesity and diabetes (Bouter et al., 2017;
40 Rosenbaum et al., 2015; Winer et al., 2016; Cani, 2019; Zmora et al., 2019), immunity-related diseases
41 (Vogelzang et al., 2018; Pronovost and Hsiao, 2019; Vatanen et al., 2016), neurodevelopmental disorders
42 (Sampson and Mazmanian, 2015; Pronovost and Hsiao, 2019), cardiovascular diseases (Tang et al., 2017;

43 Jie et al., 2017; Jonsson and Bäckhed, 2017) and cancers (Gagliani et al., 2014; Irrazábal et al., 2014;
44 Sears and Garrett, 2014).

45 The microbiota in newborn infants undergoes dynamic changes in composition, abundance and
46 diversity before reaching homeostasis at around three years of age (Yatsunenko et al., 2012; Bäckhed
47 et al., 2015; Stewart et al., 2018). Temporal colonization pattern of the intestinal microbiota during early
48 stages of life may have an important contribution to the long-term health of an individual. Early life
49 microbiota disruption had been associated with the development of metabolic and immunological diseases
50 such as Type I diabetes (Giongo et al., 2011; Vatanen et al., 2018), asthma (Stokholm et al., 2018) and
51 allergies (Madan et al., 2012a; Savage et al., 2018).

52 In preterm infants, common medical practices including Cesarean delivery, formula feeding, sterile
53 incubator nursing and extensive use of broad-spectrum antibiotics may limit the normal microbiota
54 acquisition and development (La Rosa et al., 2014; Shin et al., 2015; Deweerdt, 2018). Resultant abnormal
55 microbiota colonization in the gut may then contribute complications such as necrotizing enterocolitis
56 (NEC) and late onset sepsis (LOS) (Sharon et al., 2015; Cernada et al., 2016).

57 Necrotizing enterocolitis is characterized by rapid ischemic necrosis of intestinal mucosa, resulting
58 in high morbidity (2% - 7%) and mortality (15% - 30%) (Neu and Walker, 2011; Stoll et al., 2015). Its
59 etiology remains largely unknown and likely to be multi-factorial. Previous studies in European and
60 American countries have associated microbial dysbiosis to NEC onset. Reduction in microbiota diversity
61 and unusual species colonization were observed in NEC patients (Jacquot et al., 2011; Warner et al.,
62 2016). No causative species have been identified so far. However, an increase in Proteobacteria phyla
63 and a decrease in Firmicutes were observed before NEC onset (Mai et al., 2011; Zhou et al., 2015).
64 Besides, blooming of *Gammaproteobacteria* and under-representation of *Negativicutes* were associated
65 with disease progression (Warner et al., 2016).

66 Late onset sepsis (LOS) is another common life-threatening disease for preterm infants. It is commonly
67 defined as a systemic infection with the isolation of pathogenic bacteria from the bloodstream after 72
68 hours of life (Rao et al., 2016; Pickering et al., 2012). Preterm infants have immature gastrointestinal and
69 immune systems. Therefore, it is easier for pathogenic bacteria or bacterial toxins that can cause systemic
70 inflammation to enter the bloodstream (Schwiertz et al., 2003; Bezirtzoglou et al., 2011; Cernada et al.,
71 2016; Sharon et al., 2015; Korpela et al., 2018), thus making the intestine a potential source of infections
72 and inflammation. Previous studies showed that the LOS patients' gut microbiota was less diversified, and
73 dominated by *Staphylococci* and *Enterobacter* but underrepresented by probiotic *Bifidobacteria* (Madan
74 et al., 2012b; Tarr and Warner, 2016; Stewart et al., 2017; Korpela et al., 2018; Ficara et al., 2018).

75 NEC and LOS are two major causes of morbidity and mortality in preterm infants worldwide and
76 have been exerting economic burdens on healthcare costs (Johnson et al., 2013, 2014; Mowitz et al.,
77 2018). Although early recognition and treatment regimen has improved clinical outcomes, both diseases
78 still account for morbidities in NICU survivors (Hintz et al., 2005; Zonnenberg et al., 2019; Shah et al.,
79 2015). In China, the rate of preterm birth is as high as 7.1% (Blencowe et al., 2012) and continuous
80 improvements in neonatal health care have greatly improved the survival of preterm infants. However,
81 the risk of developing NEC and LOS increases as well. Elucidating their pathogenesis and developing
82 preventive strategies would greatly benefit the health of preterm infants. Motivated by this, we carried out
83 this longitudinal pilot study to profile the microbiota of Chinese preterm NEC and LOS patients, with
84 the aim to examine if similar alterations in microbiota correlate with the onset and progression among
85 Chinese patients. Consistent with previous studies in Western countries, we observed lower bacterial
86 diversity among Chinese NEC and LOS patients. In contrast, we found that the Chinese patients in our
87 cohort showed different bacterial compositions.

88 METHODS

89 Ethics

90 This study was approved by the joint committee of ethics of Shanghai Children's Medical Center, Shanghai
91 Jiao Tong University School of Medicine (SCMCIRB-K2013022). Detailed written informed consent was
92 obtained from parents before enrollment.

93 Patients

94 Newly born preterm infants with a gestational age less than 33 weeks and birth weight over 950g were
95 enrolled from Neonatal Intensive Care Unit (NICU) at Shanghai Children's Medical Center from July 2013

96 to December 2014. The exclusion criteria were 1) diagnosed with early-onset sepsis, 2) hepatic diseases,
97 3) renal impairment (Cr >88 μ M), 4) diagnosed with intestinal obstruction, 5) in foreseeable need of
98 major cardiovascular or abdominal surgeries (except for male circumcision or PDA ligation), 6) estimated
99 parenteral support to supply over 50% of daily caloric intake for more than four days, 7) given intravenous
100 antibiotics administration (except prophylactic regimen of cefotaxime, piperacillin-tazobactam and/or
101 metronidazole), 8) history of oral antibiotics administration, 9) grossly bloody stools at admission, and
102 10) over five days old.

103 NEC cases were defined as infants who met the criteria for Stage II and Stage III NEC diagnosis (Bell
104 et al., 1978), including radiographic intestinal dilation, ileus, pneumatosis intestinalis, and/or absent bowel
105 sounds with or without abdominal tenderness, and/or mild metabolic acidosis and thrombocytopenia. An
106 LOS case was defined if an infant 1) had a positive hemoculture or other suspicious loci of infection after
107 72 hours of life, or 2) presented with septic signs/symptoms reviewed and diagnosed independently by at
108 least two neonatologists, and had been responding well with advanced antibiotics (e.g., Meropenem) after
109 diagnosis. Infants with no infectious complications were regarded as controls.

110 **Sample collection and handling**

111 Fecal sample collection started from neonatal meconium until death or discharge, whichever came first.
112 Although we intended to collect fecal samples every day, due to working shifts and flexible clinical
113 scheduling, we set seven days as the maximum interval between two collections from every infant. Every
114 sample was collected from infants' diaper with a sterile spatula into cryogenic vials within 30 minutes of
115 defecation. Then the sample was immediately placed on dry ice and stored at - 80°C within 30 minutes
116 without additives. All samples were collected and stored before knowing the diagnosis of respective
117 patients.

118 **DNA extraction and quality control amplification and 16s rRNA gene sequencing**

119 Microbial genomic DNA was isolated from each fecal specimen using the E.Z.N.A.® Soil DNA Kit
120 (Omega Bio-Tek, Norcross, GA, U.S.) according to the manufacturer's protocols. The concentration and
121 purity of the DNA were determined by NanoDrop 2000 UV-vis spectrophotometer (Thermo Scientific,
122 Wilmington, USA), and the DNA quality was checked by 1% agarose gel electrophoresis.

123 **Broad-range PCR and High-throughput Sequencing of 16s rRNA gene amplicons**

124 The V3-V4 hypervariable regions of the bacterial 16S rRNA gene were amplified by PCR from each
125 sample using bacterial/archaeal primers 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R (5'-
126 GGACTACHVGG GTWTCTAAT-3') using a thermocycler PCR system (GeneAmp 9700, ABI, USA).
127 The PCR reactions were as follows: 3 min of denaturation at 95 °C, 27 cycles of 30 s at 95 °C, 30 s
128 annealing at 55 °C and 45 s elongation at 72 °C, and a final extension at 72 °C for 10 min. The PCR
129 reactions were performed in triplicate, with each 20 μ L mixture containing 4 μ L 5X FastPfu Buffer, 2 μ L
130 2.5 mM dNTPs, 0.8 μ L of each primer (5 μ M), 0.4 μ L FastPfu Polymerase (TransGen Biotech, Beijing,
131 China) and 10 ng template DNA. PCR products were separated from impurities and genomic DNA by
132 running in 2% agarose gels. The PCR bands were further purified using the AxyPrep DNA Gel Extraction
133 Kit (Axygen Biosciences, Union City, CA, USA), and quantified using QuantiFluor™-ST (Promega, USA)
134 according to the manufacturer's protocols. Equimolar amounts of purified amplicons were pooled and
135 paired ended sequenced (2 x 300) on an Illumina MiSeq platform (Illumina, San Diego, USA) according
136 to the standard protocols of Majorbio Bio-Pharm Technology Co. Ltd. (Shanghai, China). The reads were
137 de-multiplexed using the Illumina software and separate FASTQ files were generated for each specimen
138 and deposited to the Sequence Read Archive NCBI under the BioProject accession PRJNA470548.
139 Another public archive repository is available at figshare doi: 10.6084/m9.figshare.7205102

140 **Raw Data Processing**

141 Raw data were processed according to the standard protocols provided by Majorbio Bio-Pharm Technology
142 Co. Ltd. (Shanghai, China) as previously described (Liu et al., 2018; Wang et al., 2018). In short, raw
143 sequencing data was first de-multiplexed. Sequence reads were then subjected to quality filtering utilizing
144 Trimmomatic software (Bolger et al., 2014) and were truncated at any site with a Phred score <20 over a
145 50bp-sized window. Barcode matching with the primer mismatch from 0 to 2 nucleotides was adopted and
146 reads containing ambiguous characters were removed. After trimming, FLASH (Fast Length Adjustment
147 of Short Read) (Magoč and Salzberg, 2011), a read pre-processing software, assembled and merged the

148 paired-end reads from fragments and generated >10 bp overlapped, with the dead match ratio of 0.2.
 149 Unassembled reads were discarded. From the 192 fecal samples sequenced, a total of 7,472,400 optimized
 150 V3-V4 tags of 16s rRNA gene sequences were generated (Table S1).

151 To unbiasedly compare all the samples at the same sequencing depth, the "sub.sample" command of
 152 mothur program (version 1.30.1) (Schloss et al., 2009) was used for normalization to the smallest sample
 153 size (27994 sequences per sample). Chimera was detected and removed by UCHIME Algorithm. The
 154 effective reads were then sorted by cluster size and processed using Operational Taxonomic Units (OTUs)
 155 with 97% similarity cutoff UPARSE-OTU algorithm (implementing "cluster_otus" command) (Edgar,
 156 2013) in USEARCH(v10)(UPARSE version 7.1). The taxonomy of each 16S rRNA gene sequence was
 157 analyzed by RDP Classifier algorithm (Wang et al., 2007) against the Silva (SSU128) 16S rRNA database
 158 (Quast et al., 2012) using confidence threshold of 70%. Each sequence was assigned the taxonomy by
 159 QIIME (Caporaso et al., 2010). The representative sequences were allocated phylogenetically down to
 160 the domain, phylum, class, order, family, and genus levels (Table S2). The relative abundance of a given
 161 taxonomic group was calculated as the percentage of assigned sequences over total sequences.

162 Within-sample diversity (alpha diversity), including Shannon index and observed species richness
 163 (Sobs), was obtained using the "summary.single" command of mothur program (version 1.30.1) (Schloss
 164 et al., 2009). Between-sample diversity (beta diversity) was obtained by calculating weighted UniFrac
 165 distances between samples.

166 **Statistical and Bioinformatics Analyses**

167 ***Demographics and Clinical Sample comparisons***

168 Kruskal-Wallis test and Wilcoxon rank-sum test were used to identify statistically significant differences in
 169 continuous variables, including gestational age, birth weight, age at diagnosis and length of hospitalization.
 170 The χ^2 , or Fisher's exact test was used to identify differences in gender composition. α level was
 171 considered 0.05 for all statistical tests. Other statistical analyses not involving microbiome 16s rRNA
 172 sequencing data were performed using the "stats" package in R (v.3.5.1).

173 ***Microbiota and Bioinformatics Analyses***

174 **Disease-related Time Interval Definition** Considering that the sampling and disease onset time for
 175 each patient were not identical, to illustrate the continuous longitudinal and repeated nature of the sampling
 176 and its relationship with onset and progression of diseases, we divided the sampling span into seven time
 177 intervals:

- 178 1. early post-partum (EPP): within 3 days after birth
- 179 2. early pre-onset (EPO): from the end of EPP to at least four days before disease onset
- 180 3. late pre-onset (LPO): from the end of EPO to the disease onset; for control group patients, the
 181 equivalent onset time is set at the 16th day of life, as is the average diagnosis age of NEC and LOS
 182 groups.
- 183 4. early disease (ED): the first third interval of the whole disease span; for the control group, the
 184 equivalent ED interval is from day 16 to discharge.
- 185 5. middle disease (MD): the middle third interval of disease span
- 186 6. late disease (LD): the last third interval of disease span
- 187 7. post disease (PD): from the end of disease to discharge time-point

188 **Modeling Strategies for Comparisons** To compare the dynamics of microbiota diversity and relative
 189 taxonomic abundance preceding the disease, we applied the EPP, EPO, LPO and ED interval among all
 190 patients into our model or comparisons.

191 **Diversity Analyses** Kruskal Wallis tests were used to compare the differences in overall alpha diversity.
 192 The Mann-Whitney U test was then applied to compare two adjacent time intervals. Differences in alpha
 193 diversity over time were analyzed by a two-way repeated measures ANOVA, with the time interval
 194 (EPP, EPO, LPO, ED, MD, LD, PD) as a within-subject factor and the group (NEC, LOS, control) as a
 195 between-subject factor. If more than one sample of a patient were collected within a time interval, the
 196 average of the α diversity indices was used as one data point. Beta diversity was obtained using weighted
 197 Unifrac distance matrix and visualized through Principal Component Analysis (PCoA). The analysis of
 198 similarity (ANOSIM) (Clarke, 1993) were used to determine the dissimilarity among the clusters revealed
 199 by the PCoA plots.

200 **Taxonomy Comparisons** Zero-Inflated Beta Regression Model with Random Effects (ZIBR) and
201 Linear Mixed-effects Model (LME) were used to test the association between OTU relative abundance
202 and clinical covariates (diseases-related time intervals) for longitudinal microbiome data (Chen and Li,
203 2016). *ZIBR* and *nlme* (Pinheiro et al., 2018) R packages were utilized for each model. If more than one
204 sample of a patients were collected within a time interval, the average of relative abundance of each genus
205 was used.

206 **Scripts and Figures Archiving**

207 Figures were generated with the "*ggpubr*" (Kassambara, 2017), "*ggplot2*" (Wickham, 2016) and "*ggsci*"
208 (Xiao, 2018) packages using R(v.3.5.1). RScripts for analyses as well as input and output files are available
209 at our GitHub repository.

210 **RESULTS**

211 **Patients characteristics**

212 From July 2013 to December 2014, a total of 130 preterm infants admitted to the neonatal intensive
213 care unit (NICU) of Shanghai Children's Medical Center met the criteria of our study and a total of
214 1698 samples were collected. 192 fecal samples from 24 well-sampled preterm infants were sequenced.
215 Four subsequently developed NEC (2 in stage IIA and 2 in stage IIB) and three developed LOS (2 with
216 positive hemoculture of *Klebsiella pneumoniae*; the other one was diagnosed upon sepsis-related signs
217 and symptoms, lab test of white blood cells >20 cells/microL and her effective reaction to vancomycin).
218 The remaining 17 served as matched controls (Figure1, Table S3). Fecal samples were collected between
219 days 1 and 69 of life. Numbers of samples collected and interval of sampling varied among patients but
220 met our preset criteria of less than 7 days between sampling. The average number of sample collected for
221 NEC, LOS and control patients was 11, 14 and 6 respectively. The number of samples per patient was
222 higher in the NEC and LOS groups because the severity of the disease required longer hospitalization (p
223 = 0.046).

224 All 24 infants profiled were delivered by Cesarean section, fed on infant formula and prescribed with
225 prophylactic antibiotics regimen (cefotaxime, piperacillin-tazobactam and/or metronidazole) right after
226 they were admitted to our NICU. No infant was prescribed probiotics during the study. There was no
227 significant difference in gestational age ($p = 0.074$), birth weight ($p = 0.111$) or gender proportions ($p =$
228 0.822) among the three groups. The average age at diagnosis for both disease groups was 16 days and
229 there was no statistical difference between the groups ($p = 0.629$) (Table 1). Therefore, we assigned day
230 16 to discharge as early disease interval, day 4-8 as early pre-onset interval and day 9-15 as late pre-onset
231 interval for the control group (Table S4).

232 **Longitudinal Microbiome Diversity of NEC and LOS patients**

233 To get an overview of gut microbiota in patients, we analyzed the microbial richness of the NEC and LOS
234 patients over time. Similar to the control group, the case groups showed a decreasing trend in observed
235 species (Sobs) from early post-partum stage (EPP) to early disease (ED) stage (Fig2 (A) control group, p
236 <0.01 ; (B) NEC group, $p = 0.044$; (C) LOS group, $p = 0.013$; Dataset S1, Sheet "Sobs" two way RM
237 ANOVA, $p <0.0001$). The greatest decline in sobs was from early pre-onset (EPO) to late pre-onset
238 (LPO). However, the decrease in the disease groups was less significant than the control group (control
239 group $p = 0.0004$, NEC group $p = 0.18$, LOS group $p = 0.066$). The Sobs then stabilized from LPO
240 onward with no significant difference between adjacent time intervals.

241 Next, we analyzed gut microbiome evenness over time. Similar to Sobs, the Shannon indices decreased
242 significantly from the early post-partum (EPP) to early disease (ED) stage (Fig3(A) control group 2.768
243 to 1.004, $p = 0.04$; (B) NEC group, 3.141 to 0.578, $p = 0.01$; (C) LOS group, 2.641 to 0.470, $p = 0.01$).

244 Two way RM ANOVA showed significant Shannon index divergent among three groups before disease
245 onset (Dataset S1, sheet "Shannon", EPP to ED, $p = 0.0017$). Moreover, during early disease stage, the
246 Shannon indices were different among three groups (Fig4, facet "early disease", $p = 0.0037$), suggesting
247 that microbiota distortion may precede NEC and LOS onset. As diseases progressed, the NEC group
248 differed significantly with the LOS group during middle disease interval but insignificantly during late
249 disease interval (Fig4 facet "middle disease", $p = 0.034$; facet "late disease", $p = 0.750$). Upon alleviation
250 of both diseases, the Shannon indices rose back to the early pre-onset levels(Fig3 (B) NEC group. early

251 pre-onset at 1.925 vs. post disease at 1.320, $p = 0.79$; (C) LOS group, early pre-onset at 2.473 vs. post
252 disease at 1.463, $p = 0.16$).

253 Kinetics of Microbiome Composition

254 To compare the beta-diversity of the three groups over time, we applied Principal Component Analysis
255 (PCoA) to weighted UniFrac distance matrix and used the analysis of similarity (ANOSIM) (Clarke, 1993)
256 to determine the dissimilarity of the microbial composition among the groups. Bacterial composition
257 of three groups showed non-significant difference during the early post-partum interval (ANOSIM $R =$
258 0.007 , $p = 0.385$), with the first principal coordinates accounted for 33.01%(Fig5 (A)). Then the cluster of
259 each group continued to separate from one another. The first principal coordinate one (PC1) increased
260 from 33.01% at the early post-partum to 35.23% at the early pre-onset stage, 38.36% at the late pre-onset
261 stage and eventually reaching 42.32% at the early disease stage (Fig5 (B) ANOSIM $R = 0.151$, $p =$
262 0.087 , (C) ANOSIM $R = 0.255$, $p = 0.015$, to (D) $R = 0.193$, $p = 0.077$). This continuous increase
263 in beta-diversity suggested that the phylogenetic composition of the patients' microbiome started to
264 deviate from the control group before the onset of diseases. As diseases progressed, the phylogenetic
265 similarity between the NEC and the LOS disease groups diverged further and peaked at 59.53% in middle
266 disease stage (ANOSIM $R = 0.317$, $p = 0.028$) then came down gradually to 42.8% at post disease
267 stage (Fig5 (E) ANOSIM $R = 0.317$, $p = 0.028$, to (G) ANOSIM $R = 0.203$, $p = 0.045$). This trend in
268 phylogenetic dissimilarity suggested that the microbiome composition of the NEC and LOS patients
269 might have deviated from normal even before the onset of diseases. Also, the further separation between
270 the NEC and the LOS groups could be a result of different treatment strategies.

271 Colonization Trend at The Genus Level

272 In the analyses of intestinal microbiome alpha(Fig2, Fig3, Fig4) and beta diversity(Fig5), detectable
273 differences were observed among the three groups, especially during the transition from the LPO to ED
274 stage. This indicated that the microbiota assembly differences between the case groups and control group.
275 To further investigate which microbiota composition was correlated with the onset and/or progression of
276 NEC and LOS, we tracked the longitudinal compositional changes in the abundance of each genera. We
277 filtered the genus of over 10% relative abundance among all samples and plotted relative abundance over
278 time(Fig6).

279 At the early post-partum stage, all three groups showed high proportion of *Lactococcus*, *Bacillus*
280 and *Pseudomonas*. However, ZIBR model the disease groups showed significantly higher OTUs that
281 matched to *Bacillus* (NEC 15.05% and LOS 15.97% compared to 6.02% of control, $p = 0.032$) and
282 *Solibacillus* (8.88% in NEC and 9.61% in LOS compared to 3.65% of control, $p = 0.047$) from the case
283 groups (Dataset S2). Moreover, *Enterococcus* proportion (Fig6(B), purple area) was much higher in
284 LOS patients (20.72%) than the normal controls (6.66%, $p = 0.048$, Fig6(A), purple area) but almost
285 absent in NEC patients (0.51%) (Fig6(B)). While all three groups showed increases in *Klebsiella* and
286 *Escherichia-Shigella* and decrease in *Lactococcus* from EPP to ED, the rates of change were different
287 among the three groups. The LOS group exhibited the most drastic changes, with a rapidly increase of
288 *Klebsiella* (from 4.71% to 58.90%, $p = 0.017$), *Escherichia-Shigella* (from 2.02% to 18.16%, $p = 0.034$)
289 and *Streptococcus* (from 1.22% to 12.68%, $p = 0.029$)(Fig6(C)). Together, these three genera accounted
290 for almost 100% of all bacteria (Fig6(C)). In addition, *Lactococcus* decreased more rapidly than the other
291 groups, from 24.54% at EPP to 0.94% before LPO (Fig6(C) magenta area, $p = 0.037$).

292 Besides, the increase of *Klebsiella* was the most minimal in NEC patients (Fig6(B) grey area,
293 from 7.17% at EPP to 35.63% at ED). Moreover, a rapid surge of *Enterococcus*, *Staphylococcus* and
294 *Streptococcus* from EPO to ED was only observed in NEC patients (Fig6(B), purple, dark and light blue
295 area).

296 As NEC and LOS progressed with medical intervention, the genus in case groups underwent another
297 round of drastic changes. Most notably, the fluctuation of *Enterococcus*, *Klebsiella*, *Staphylococcus* and
298 *Peptoclostridium* during the disease stages (Fig6(B) and (C), stage ED to LD), which might be resultant
299 from different healthcare strategies applied in two groups. Interestingly, as patients approached remission,
300 the composition became more balanced and resembled more to that of the normal control, except for a
301 higher level of *Clostridium*. In summary, relative to patients in the control group, we observed different
302 patterns of temporal alterations in bacterial composition among NEC and LOS patients. Rapid changes in
303 relative abundance of certain genera were revealed as early as early pre-onset of stages and were the most
304 notable in LOS patients.

305 **DISCUSSION**

306 In this pilot study, we intend to investigate the etiopathology of NEC and LOS in Chinese preterm infants
307 from the perspective of intestinal microbiota. We profiled the gut microbiome of NEC and LOS preterm
308 infants from birth to death or discharge. Some of our findings are similar to previous larger-scale studies.
309 Mainly, infants who developed NEC or LOS exhibit a different gut microbiota colonization pattern relative
310 to the controls. Case groups showed a decline in diversity, although to a different extent. Moreover, NEC
311 and LOS infants' intestines were prone to harbor potential pathogens prior to and after disease onsets,
312 such as *Enterococcus*, *Staphylococcus*, *Peptoclostridium* and *Streptococcus*. There were also findings
313 unique to this study will be discussed in the following paragraphs.

314 To our knowledge, few studies have analyzed stool bacterial alpha diversity in preterm infants as early
315 as three days after birth. Unexpectedly, within three days after birth (i.e., early post-partum interval), the
316 bacterial diversity of all three groups was the highest compared to the following stages. At this point, we
317 do not know if this high bacterial richness and evenness within three days of life are universal. More
318 data, especially from other countries, are needed to support this finding. After three days, the microbial
319 alpha diversity exhibited a declining trend in both disease groups and the control group. The number of
320 colonized species (sobs index) during this interval, in line with previous works (Mai et al., 2011, 2013),
321 remained similar before disease onset in both case and control groups, suggesting a minor role of bacterial
322 richness in the disease onset. Besides, a rapid decline in alpha diversity during the pre-onset stages was
323 observed. This could be resultant from the standardized antibiotic regimen right after admission into our
324 NICU. However, previous studies showed that the pervasive effect of antibiotics in reducing richness and
325 evenness arose only after 1 week to 2 months of administration (DiGiulio et al., 2008; Dethlefsen and
326 Relman, 2011; Fouhy et al., 2012; Greenwood et al., 2014; Tanaka et al., 2009). Thus, more research is
327 needed to identify if additional factor(s) is involved in this rapid decline.

328 The role of empiric prophylactic antibiotics in NEC or LOS is controversial. In animal models,
329 antibiotics eliminating Gram-negative bacteria enhance gut function and diminish mucosal injury to
330 the bowel thus preventing necrotizing enterocolitis or bacterial leakage into the bloodstream (Carlisle
331 et al., 2011; Jensen et al., 2013; Birck et al., 2015). In clinical practices, broad-spectrum antibiotics
332 (the most commonly prescribed medications in the NICU) are recommended to empirically prevent and
333 treat both NEC and LOS (Bury and Tudehope, 2001; Brook, 2008; Kimberlin et al., 2018). However,
334 antibiotics can further induce microbiome dysbiosis that may increase the risk of developing these diseases
335 and exacerbate the severity (Gibson et al., 2015; Kuppala et al., 2011; Martinez et al., 2017; Cantey
336 et al., 2018). Our results showed limited differences in bacterial diversity and composition between two
337 case groups and the control group despite continuously antibiotics administration. Although our results
338 are in line with the dysbiotic effect of antibiotics, there was not enough evidence to support whether
339 antibiotics per se induced or prevented NEC and LOS. Further studies are needed to confirm the causative
340 relationships.

341 Furthermore, microbiota beta-diversity, which measures the phylogenetic similarity, drifted away
342 continuously among three groups before the onset of both diseases. These findings were inconsistent
343 with a previous study where the microbiota of NEC patients were shown to be similar to that of the
344 healthy controls at three days before onset (Mai et al., 2011). With regards to the LOS patients, it is also
345 inconsistent with the previous study where similar microbiota diversity was observed in LOS patients
346 during the disease and 72 hours before onset (Mai et al., 2013). These discrepancies could be a result
347 of differences in collection time points or differences in patients' demographics. Further studies are
348 necessary to address these issues. As the diseases progressed, the beta-diversity of the NEC group and
349 the LOS group separated further but converged again when diseases were alleviated. The exact cause
350 of this divergence was not clear. It could be related to different treatment strategies or some intrinsic
351 pathophysiology differences between the two diseases. Further studies should provide more insight.

352 In addition to bacterial diversity, we also tracked longitudinal changes in composition at the genus level
353 by plotting the relative abundance over time. Overall, the control group exhibited more stable microbiota
354 assembly, without drastic fluctuation in genus abundance and with less dominance of facultative anaerobes
355 such as *Enterococcus* and *Staphylococcus* (Gibson et al., 2015; La Rosa et al., 2014; Grier et al., 2017).
356 Based on our ZIBR model, an over-represented *Bacillus* and *Solibacillus* were detected during the pre-
357 onset stages in case groups. However, both genera diminished after disease onset suggesting that the initial
358 microbiota composition in preterms might contribute to their future health outcomes. Previous studies
359 also observed a surge in Proteobacteria phyla (Mai et al., 2013, 2011) preceding LOS and NEC onset. In

line with this, LOS patients in our cohort were also characterized by a higher abundance of *Klebsiella* in their intestinal communities. On the contrary, NEC infants presented overgrowth of *Streptococcus* and *Staphylococcus* (both belong to phyla *Firmicutes*) before disease onset. Further work is warranted to identify specific genera and trends in association with the onset of NEC and/or LOS.

Diarrhea is one of the typical symptoms in NEC patients and *Peptoclostridium* is conventionally regarded as a causative pathogen of hospital-acquired infectious diarrhea (Rodriguez et al., 2016; Pereira et al., 2016). In our study, we identified a transient bloom of *Peptoclostridium* in late NEC stage that coincided with the diarrhea symptom, possibly explaining the mechanism of common diarrhea symptom in NEC patients. Moreover, mucosal-adhering bacteria such as *Enterococcus* and *Streptococcus* were highly represented in pediatric enterocolitis (Normann et al., 2013; Zhou et al., 2016). Consistent with this, NEC patients from our cohort exhibited a higher abundance of *Enterococcus* during disease stage.

In contrast, the composition of our LOS patient samples was very different from previous studies where *Enterobacteria* and *Staphylococcus* were identified as the most prevalent genera (Stewart et al., 2017; Mai et al., 2013). In our cohort of LOS patients, *Klebsiella* was the most dominated genus. LOS is frequently caused by organisms, mostly bacteria, that translocate from the intestinal tract to the bloodstream. Consistently, *Klebsiella* was detected in hemoculture in two out of two of our LOS patients (hemoculture was not performed for the third patient). In addition, *Klebsiella pneumoniae* is one of the most common causes of sepsis in preterm patients of our hospital (JL and LH personal observation), suggesting that the most dominant and eventually infectious bacteria may be more specific to the environment.

Another notable point in our cohort was almost absent *Bifidobacteria*, an anaerobe that can ferment milk oligosaccharides (Gomez-Gallego et al., 2016) and thus commonly detected among breastfed infants (Murphy et al., 2017). We speculate that this extremely low level in our cohort was due to the lack of breastfeeding in the sterile hospital environment, being nurtured in the sterile NICU environment, continuous administration of antibiotics or the combinations of the above. Although *Bifidobacteria* has been generally considered a probiotic that serves to protect neonates against necrotizing enterocolitis and systemic infection (Nakayama et al., 2003; Khodayar-Pardo et al., 2014; Hermansson et al., 2019), recent randomized controlled trials are showing paradoxical results (Hays et al., 2016; Singh et al., 2019). Further studies on the role of probiotics in optimizing preterm infants' microbiota should address their effectiveness in preventing NEC and LOS.

This study was limited to only one hospital in one specific region (Shanghai) in China so how far these findings can be extrapolated remains to be determined. In addition, our sample size was relatively small since both diseases are rare (Neu and Walker, 2011; Cohen-Wolkowicz et al., 2009). Among the 1148 preterm infants admitted from July 2013 to December 2014, only five developed NEC and seven developed LOS. Nevertheless, this pilot study has provided essential information about NEC and LOS preterm patients within the Chinese population and serves as a starting point for future investigations into the etiology and pathogenesis of both diseases in the nation.

CONCLUSIONS

In this longitudinal study, we used next generation-sequencing to profile the microbiota of 24 Chinese preterm infants from birth to discharge. Among them, four developed NEC and three developed LOS. To our knowledge, this is the first profiling of gut microbiota in NEC and LOS patients among the Asian population. Reduction in intestinal microbiota diversity and divergence of phylogenetic similarity from the control infants over time associated with both NEC and LOS onset. Overgrowth of potentially pathogenic genus *Enterococcus*, *Streptococcus* and *Peptoclostridium* were observed in NEC cases while *Klebsiella* was recognized as the dominant genus in LOS cases. In summary, our findings suggest that both NEC and LOS are dynamic processes involving abnormal microbiota assembly. This study is a starting point for further studying of microbial factors involved in preterm-associated complications in China. Accumulation of more data within China and perhaps from neighboring countries will allow us to build microbial signatures that can assist early diagnosis and development of novel treatment.

ACKNOWLEDGMENTS

We sincerely thank all the patients and their family in supporting this study. We extend our thanks to the medical and research staffs of the Shanghai Children's Medical Center. We also thank Ka Ming Pang,

412 Arin Nam and Christina Meyer for critical reviews of this manuscript.

413 REFERENCES

- 414 Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatchevadatchary, P., Li, Y., Xia, Y., Xie, H., and
415 Zhong, H. (2015). Dynamics and stabilization of the human gut microbiome during the first year of
416 life. *Cell Host & Microbe*, 17(5):690–703.
- 417 Bell, M. J., Ternberg, J. L., Feigin, R. D., Keating, J. P., Marshall, R., Barton, L., and Brotherton, T.
418 (1978). Neonatal necrotizing enterocolitis. therapeutic decisions based upon clinical staging. *Annals of*
419 *surgery*, 187(1):1.
- 420 Bezirtzoglou, E., Tsiotsias, A., and Welling, G. W. (2011). Microbiota profile in feces of breast-and
421 formula-fed newborns by using fluorescence in situ hybridization (fish). *Anaerobe*, 17(6):478–482.
- 422 Birck, M. M., Nguyen, D. N., Cilieborg, M. S., Kamal, S. S., Nielsen, D. S., Damborg, P., Olsen, J. E.,
423 Lauridsen, C., Sangild, P. T., and Thymann, T. (2015). Enteral but not parenteral antibiotics enhance
424 gut function and prevent necrotizing enterocolitis in formula-fed newborn preterm pigs. *American*
425 *Journal of Physiology-Heart and Circulatory Physiology*.
- 426 Blencowe, H., Cousens, S., Oestergaard, M. Z., Chou, D., Moller, A. B., Narwal, R., Adler, A., Vera,
427 G. C., Rohde, S., and Say, L. (2012). National, regional, and worldwide estimates of preterm birth
428 rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and
429 implications. *The Lancet*, 379(9832):2162–2172.
- 430 Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for illumina sequence
431 data. *Bioinformatics*, 30(15):2114–2120.
- 432 Bouter, K. E., van Raalte, D. H., Groen, A. K., and Nieuwdorp, M. (2017). Role of the gut microbiome in
433 the pathogenesis of obesity and obesity-related metabolic dysfunction. *Gastroenterology*, 152(7):1671–
434 1678.
- 435 Brook, I. (2008). Microbiology and management of neonatal necrotizing enterocolitis. *American journal*
436 *of perinatology*, 25(02):111–118.
- 437 Bury, R. G. and Tudehope, D. (2001). Enteral antibiotics for preventing necrotizing enterocolitis in low
438 birthweight or preterm infants. *Cochrane Database of Systematic Reviews*, 2(2).
- 439 Cani, P. D. (2019). Severe obesity and gut microbiota: does bariatric surgery really reset the system? *Gut*,
440 68(1):5–6.
- 441 Cantey, J. B., Pyle, A. K., Wozniak, P. S., Hynan, L. S., and Sánchez, P. J. (2018). Early antibiotic
442 exposure and adverse outcomes in preterm, very low birth weight infants. *The Journal of pediatrics*,
443 203:62–67.
- 444 Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N.,
445 Peñ̄a, A. G., Goodrich, J. K., and Gordon, J. I. (2010). Qiime allows analysis of high-throughput
446 community sequencing data. *Nature methods*, 7(5):335.
- 447 Carlisle, E. M., Poroyko, V., Caplan, M. S., Alverdy, J. A., and Liu, D. (2011). Gram negative bacteria
448 are associated with the early stages of necrotizing enterocolitis. *PLoS one*, 6(3):e18084.
- 449 Cernada, M., Bäuerl, C., Serna, E., Collado, M. C., Martínez, G. P., and Vento, M. (2016). Sepsis in
450 preterm infants causes alterations in mucosal gene expression and microbiota profiles compared to
451 non-septic twins. *Scientific Reports*, 6(1):25497.
- 452 Chen, E. Z. and Li, H. (2016). A two-part mixed-effects model for analyzing longitudinal microbiome
453 compositional data. *Bioinformatics*, 32(17):2611–2617.
- 454 Clarke, K. R. (1993). Non-parametric multivariate analyses of changes in community structure. *Australian*
455 *journal of ecology*, 18(1):117–143.
- 456 Cohen-Wolkowicz, M., Moran, C., Benjamin, D. K., Cotten, C. M., Clark, R. H., Benjamin Jr, D. K., and
457 Smith, P. B. (2009). Early and late onset sepsis in late preterm infants. *The Pediatric infectious disease*
458 *journal*, 28(12):1052.
- 459 Dethlefsen, L. and Relman, D. A. (2011). Incomplete recovery and individualized responses of the human
460 distal gut microbiota to repeated antibiotic perturbation. *Proceedings of the National Academy of*
461 *Sciences*, 108(Supplement 1):4554–4561.
- 462 Deweerdt, S. (2018). How baby’s first microbes could be crucial to future health. *Nature*, 555(7695):S18–
463 S19.
- 464 DiGiulio, D. B., Romero, R., Amogan, H. P., Kusanovic, J. P., Bik, E. M., Gotsch, F., Kim, C. J., Erez, O.,

- 465 Edwin, S., and Relman, D. A. (2008). Microbial prevalence, diversity and abundance in amniotic fluid
466 during preterm labor: a molecular and culture-based investigation. *PLoS one*, 3(8):e3056.
- 467 Edgar, R. C. (2013). Uparse: highly accurate otu sequences from microbial amplicon reads. *Nature*
468 *methods*, 10(10):996.
- 469 Ficara, M., Pietrella, E., Spada, C., Della Casa Muttini, E., Lucaccioni, L., Iughetti, L., and Berardi, A.
470 (2018). Changes of intestinal microbiota in early life. *The Journal of Maternal-Fetal & Neonatal*
471 *Medicine*, pages 1–8.
- 472 Fouhy, F., Guinane, C. M., Hussey, S., Wall, R., Ryan, C. A., Dempsey, E. M., Murphy, B., Ross,
473 R. P., Fitzgerald, G. F., Stanton, C., and Cotter, P. D. (2012). High-throughput sequencing reveals the
474 incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with
475 ampicillin and gentamicin. *Antimicrobial agents and chemotherapy*, 56(11):5811–5820.
- 476 Gagliani, Nicola, Hu, Bo, Huber, Samuel, Elinav, and Richard (2014). The fire within: Microbes
477 inflame tumors. *Cell*, 157(4):776–783.
- 478 Gibson, M. K., Crofts, T. S., and Dantas, G. (2015). Antibiotics and the developing infant gut microbiota
479 and resistome. *Current opinion in microbiology*, 27:51–56.
- 480 Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Novelo, L. L., Casella, G., Drew, J. C., Ilonen, J.,
481 Knip, M., Hyöty, H., Veijola, R., Simell, T., Simell, O., Neu, J., Wasserfall, C. H., Schatz, D., Atkinson,
482 M. A., and Triplett, E. W. (2011). Toward defining the autoimmune microbiome for type 1 diabetes.
483 *The ISME journal*, 5(1):82.
- 484 Gomez-Gallego, C., Garcia-Mantrana, I., Salminen, S., and Collado, M. C. (2016). The human milk
485 microbiome and factors influencing its composition and activity. In *Seminars in Fetal and Neonatal*
486 *Medicine*, volume 21, pages 400–405. Elsevier.
- 487 Greenwood, C., Morrow, A. L., Lagomarcino, A. J., Altaye, M., Taft, D. H., Yu, Z., Newburg, D. S.,
488 Ward, D. V., and Schibler, K. R. (2014). Early empiric antibiotic use in preterm infants is associated
489 with lower bacterial diversity and higher relative abundance of enterobacter. *The Journal of pediatrics*,
490 165(1):23–29.
- 491 Grier, A., Qiu, X., Bandyopadhyay, S., Holden-Wiltse, J., Kessler, H. A., Gill, A. L., Hamilton, B., Huyck,
492 H., Misra, S., Mariani, T. J., Ryan, R. M., Scholer, L., Scheible, K. M., Lee, Y.-H., Caserta, M. T.,
493 Pryhuber, G. S., and Gill, S. R. (2017). Impact of prematurity and nutrition on the developing gut
494 microbiome and preterm infant growth. *Microbiome*, 5(1):158.
- 495 Hays, S., Jacquot, A., Gauthier, H., Kempf, C., Beissel, A., Pidoux, O., Jumas-Bilak, E., Decullier, E.,
496 Lachambre, E., and Beck, L. (2016). Probiotics and growth in preterm infants: A randomized controlled
497 trial, premapro study. *Clinical Nutrition*, 35(4):802–811.
- 498 Hermansson, H., Kumar, H., Collado, M. C., Salminen, S., Isolauri, E., and Rautava, S. (2019). Breast
499 milk microbiota is shaped by mode of delivery and intrapartum antibiotic exposure. *Frontiers in*
500 *nutrition*, 6.
- 501 Hintz, S. R., Kendrick DEStoll, B. J., Vohr, B. R., Fanaroff, A. A., Donovan, E. F., Poole, W. K., Blakely,
502 M. L., Wright, L., and Higgins, R. (2005). Neurodevelopmental and growth outcomes of extremely
503 low birth weight infants after necrotizing enterocolitis. *Pediatrics*, 115(3):696–703.
- 504 Irrazábal, T., Belcheva, A., Girardin, S. E., Martin, A., and Philpott, D. J. (2014). The multifaceted role of
505 the intestinal microbiota in colon cancer. *Molecular Cell*, 54(2):309–320.
- 506 Jacquot, A., Neveu, D., Aujoulat, F., Mercier, G., Marchandin, H., Jumas-Bilak, E., and Picaud, J.-C.
507 (2011). Dynamics and clinical evolution of bacterial gut microflora in extremely premature patients.
508 *The Journal of pediatrics*, 158(3):390–396.
- 509 Jensen, M. L., Thymann, T., Cilieborg, M. S., Lykke, M., Mølbak, L., Jensen, B. B., Schmidt, M.,
510 Kelly, D., Mulder, I., and Burrin, D. G. (2013). Antibiotics modulate intestinal immunity and prevent
511 necrotizing enterocolitis in preterm neonatal piglets. *American Journal of Physiology-Heart and*
512 *Circulatory Physiology*.
- 513 Jie, Z., Xia, H., Zhong, S. L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., and Zhao, H. (2017).
514 The gut microbiome in atherosclerotic cardiovascular disease. *Nature Communications*, 8(1).
- 515 Johnson, T. J., Patel, A. L., Bigger, H. R., Engstrom, J. L., and Meier, P. P. (2014). Economic benefits
516 and costs of human milk feedings: a strategy to reduce the risk of prematurity-related morbidities in
517 very-low-birth-weight infants. *Advances in nutrition*, 5(2):207–212.
- 518 Johnson, T. J., Patel, A. L., Jegier, B. J., Engstrom, J. L., and Meier, P. P. (2013). Cost of morbidities in
519 very low birth weight infants. *The Journal of pediatrics*, 162(2):243–249.

- 520 Jonsson, A. L. and Bäckhed, F. (2017). Role of gut microbiota in atherosclerosis. *Nature Reviews*
521 *Cardiology*, 14(2):79.
- 522 Kassambara, A. (2017). ggpubr:“ggplot2” based publication ready plots. r package version 0.1. 6.
- 523 Khodayar-Pardo, P., Mira-Pascual, L., Collado, M., and Martinez-Costa, C. (2014). Impact of lactation
524 stage, gestational age and mode of delivery on breast milk microbiota. *Journal of Perinatology*,
525 34(8):599.
- 526 Kimberlin, D. W., Brady, M. T., Jackson, M. A., and Long, S. S. (2018). *Red Book: 2018-2021 report of*
527 *the committee on infectious diseases*. American academy of pediatrics, 31 edition.
- 528 Korpela, K., Blakstad, E. W., Moltu, S. J., Strømme, K., Nakstad, B., Rønnestad, A. E., Brække, K.,
529 Iversen, P. O., Drevon, C. A., and Vos, W. (2018). Intestinal microbiota development and gestational
530 age in preterm neonates. *Scientific reports*, 8(1):2453.
- 531 Kuppala, V. S., Meinzen-Derr, J., Morrow, A. L., and Schibler, K. R. (2011). Prolonged initial empirical
532 antibiotic treatment is associated with adverse outcomes in premature infants. *The Journal of pediatrics*,
533 159(5):720–725.
- 534 La Rosa, P. S., Warner, B. B., Zhou, Y., Weinstock, G. M., Sodergren, E., Hall-Moore, C. M., Stevens,
535 H. J., Bennett, William E. J., Shaikh, N., Linneman, L. A., Hoffmann, J. A., Hamvas, A., Deych, E.,
536 Shands, B. A., Shannon, W. D., and Tarr, P. I. (2014). Patterned progression of bacterial populations in
537 the premature infant gut. *Proceedings of the National Academy of Sciences*, 111(34):12522–12527.
- 538 Liu, Y., Li, J., Jin, Y., Zhao, L., Zhao, F., Feng, J., Li, A., and Wei, Y. (2018). Splenectomy leads
539 to amelioration of altered gut microbiota and metabolome in liver cirrhosis patients. *Frontiers in*
540 *Microbiology*, 9.
- 541 Madan, J. C., Farzan, S. F., Hibberd, P. L., and Karagas, M. R. (2012a). Normal neonatal microbiome
542 variation in relation to environmental factors, infection and allergy. *Current opinion in pediatrics*,
543 24(6):753.
- 544 Madan, J. C., Salari, R. C., Saxena, D., Davidson, L., O’Toole, G. A., Moore, J. H., Sogin, M. L.,
545 Foster, J. A., Edwards, W. H., Palumbo, P., and Hibberd, P. L. (2012b). Gut microbial colonisation in
546 premature neonates predicts neonatal sepsis. *Archives of Disease in Childhood-Fetal and Neonatal*
547 *Edition*, 97(6):F456–F462.
- 548 Magoč, T. and Salzberg, S. L. (2011). Flash: fast length adjustment of short reads to improve genome
549 assemblies. *Bioinformatics*, 27(21):2957–2963.
- 550 Mai, V., Torrazza, R. M., Ukhanova, M., Wang, X., Sun, Y., Li, N., Shuster, J., Sharma, R., Hudak, M. L.,
551 and Neu, J. (2013). Distortions in development of intestinal microbiota associated with late onset sepsis
552 in preterm infants. *PloS one*, 8(1):e52876.
- 553 Mai, V., Young, C. M., Ukhanova, M., Wang, X., Sun, Y., Casella, G., Theriaque, D., Li, N., Sharma, R.,
554 Hudak, M., and Neu, J. (2011). Fecal microbiota in premature infants prior to necrotizing enterocolitis.
555 *PloS one*, 6(6):e20647.
- 556 Martinez, F. E., Wag, F., Leone, C. R., Mfb, D. A., Guinsburg, R., Jda, M., Msd, V., Stm, M., Carvalho,
557 W. B., and Lmss, R. (2017). Early empiric antibiotic use is associated with delayed feeding tolerance
558 in preterm infants: A retrospective analysis. *Journal of pediatric gastroenterology and nutrition*,
559 65(1):107–110.
- 560 Mowitz, M. E., Dukhovny, D., and Zupancic, J. A. (2018). The cost of necrotizing enterocolitis in
561 premature infants. In *Seminars in Fetal and Neonatal Medicine*. Elsevier.
- 562 Murphy, K., Curley, D., O’Callaghan, T. F., O’Shea, C.-A., Dempsey, E. M., O’Toole, P. W., Ross, R. P.,
563 Ryan, C. A., and Stanton, C. (2017). The composition of human milk and infant faecal microbiota over
564 the first three months of life: a pilot study. *Scientific reports*, 7:40597.
- 565 Nakayama, M., Yajima, M., Hatano, S., Yajima, T., and Kuwata, T. (2003). Intestinal adherent bacteria
566 and bacterial translocation in breast-fed and formula-fed rats in relation to susceptibility to infection.
567 *Pediatric research*, 54(3):364.
- 568 Neu, J. and Walker, W. A. (2011). Necrotizing enterocolitis. *New England Journal of Medicine*,
569 364(3):255–264.
- 570 Normann, E., Fahlén, A., Engstrand, L., and Lilja, H. E. (2013). Intestinal microbial profiles in extremely
571 preterm infants with and without necrotizing enterocolitis. *Acta paediatrica*, 102(2):129–136.
- 572 Pereira, F. L., Júnior, C. A. O., Silva, R. O., Dorella, F. A., Carvalho, A. F., Almeida, G. M., Leal, C. A.,
573 Lobato, F. C., and Figueiredo, H. C. (2016). Complete genome sequence of peptoclostridium difficile
574 strain z31. *Gut pathogens*, 8(1):11.

- 575 Pickering, L. K., Baker, C. J., and Kimberlin, D. W. (2012). *Red Book, (2012): Report of the Committee*
576 *on Infectious Diseases*. Am Acad Pediatrics.
- 577 Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D., and R Core Team (2018). *nlme: Linear and Nonlinear*
578 *Mixed Effects Models*. R package version 3.1-137.
- 579 Pronovost, G. N. and Hsiao, E. Y. (2019). Perinatal interactions between the microbiome, immunity, and
580 neurodevelopment. *Immunity*, 50(1):18–36.
- 581 Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., and Glöckner, F. O.
582 (2012). The silva ribosomal rna gene database project: improved data processing and web-based tools.
583 *Nucleic acids research*, 41(D1):D590–D596.
- 584 Rao, S. C., Srinivasjois, R., and Moon, K. (2016). One dose per day compared to multiple doses per day
585 of gentamicin for treatment of suspected or proven sepsis in neonates. *Cochrane database of systematic*
586 *reviews*, 6(12).
- 587 Rodriguez, C., Van Broeck, J., Taminiau, B., Delmée, M., and Daube, G. (2016). Clostridium difficile
588 infection: early history, diagnosis and molecular strain typing methods. *Microbial pathogenesis*,
589 97:59–78.
- 590 Rosenbaum, M., Knight, R., and Leibel, R. L. (2015). The gut microbiota in human energy homeostasis
591 and obesity. *Trends in Endocrinology & Metabolism*, 26(9):493–501.
- 592 Sampson, T. R. and Mazmanian, S. K. (2015). Control of brain development, function, and behavior by
593 the microbiome. *Cell Host & Microbe*, 17(5):565–576.
- 594 Savage, J. H., Lee-Sarwar, K. A., Sordillo, J., Bunyavanich, S., Zhou, Y., O'Connor, G., Sandel, M.,
595 Bacharier, L. B., Zeiger, R., Sodergren, E., Weinstock, G. M., Gold, D. R., Weiss, S. T., and Litonjua,
596 A. A. (2018). A prospective microbiome-wide association study of food sensitization and food allergy
597 in early childhood. *Allergy*, 73(1):145–152.
- 598 Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A.,
599 Oakley, B. B., Parks, D. H., and Robinson, C. J. (2009). Introducing mothur: open-source, platform-
600 independent, community-supported software for describing and comparing microbial communities.
601 *Applied and environmental microbiology*, 75(23):7537–7541.
- 602 Schwieritz, A., Gruhl, B., Löbnitz, M., Michel, P., Radke, M., and Blaut, M. (2003). Development of the
603 intestinal bacterial composition in hospitalized preterm infants in comparison with breast-fed, full-term
604 infants. *Pediatric research*, 54(3):393.
- 605 Sears, C. L. and Garrett, W. S. (2014). Microbes, microbiota, and colon cancer. *Cell Host & Microbe*,
606 15(3):317–328.
- 607 Shah, J., Jefferies, A. L., Yoon, E. W., Lee, S. K., and Shah, P. S. (2015). Risk factors and outcomes of
608 late-onset bacterial sepsis in preterm neonates born at less than 32 weeks' gestation. *American journal*
609 *of perinatology*, 32(07):675–682.
- 610 Sharon, U., Alain, S., Prakesh Kumar, S., David, M., and O'Connor, D. L. (2015). Gut microbiota of the
611 very-low-birth-weight infant. *Pediatric Research*, 77(1-2):205.
- 612 Shin, H., Pei, Z., Martinez, K. A., Rivera-Vinas, J. I., Mendez, K., Cavallin, H., and Dominguez-Bello,
613 M. G. (2015). The first microbial environment of infants born by c-section: the operating room
614 microbes. *Microbiome*, 3(1):59.
- 615 Singh, B., Shah, P. S., Afifi, J., Simpson, C. D., Mitra, S., Dow, K., and El-Naggar, W. (2019). Probiotics
616 for preterm infants: A national retrospective cohort study. *Journal of Perinatology*, page 1.
- 617 Stewart, C. J., Ajami, N. J., O'Brien, J. L., Hutchinson, D. S., Smith, D. P., Wong, M. C., Ross, M. C.,
618 Lloyd, R. E., Doddapaneni, H., Metcalf, G. A., Muzny, D., Gibbs, R. A., Vatanen, T., Huttenhower, C.,
619 Xavier, R. J., Rewers, M., Hagopian, W., Toppari, J., Ziegler, A.-G., She, J.-X., Akolkar, B., Lernmark,
620 A., Hyoty, H., Vehik, K., Krischer, J. P., and Petrosino, J. F. (2018). Temporal development of the gut
621 microbiome in early childhood from the teddy study. *Nature*, 562(7728):583.
- 622 Stewart, C. J., Embleton, N. D., Marrs, E. C. L., Smith, D. P., Fofanova, T., Nelson, A., Skeath, T., Perry,
623 J. D., Petrosino, J. F., and Berrington, J. E. (2017). Longitudinal development of the gut microbiome
624 and metabolome in preterm neonates with late onset sepsis and healthy controls. *Microbiome*, 5(1):75.
- 625 Stokholm, J., Blaser, M. J., Thorsen, J., Rasmussen, M. A., Waage, J., Vinding, R. K., Schoos, A.-M. M.,
626 Kunøe, A., Fink, N. R., Chawes, B. L., Bønnelykke, K., Brejnrod, A. D., Mortensen, M. S., Al-Soud,
627 W. A., Sørensen, S. J., and Bisgaard, H. (2018). Maturation of the gut microbiome and risk of asthma
628 in childhood. *Nature communications*, 9(1):141.
- 629 Stoll, B. J., Hansen, N. I., Bell, E. F., Walsh, M. C., Carlo, W. A., Shankaran, S., Laptook, A. R., Sánchez,

- 630 P. J., Van Meurs, K. P., Wyckoff, M., Das, A., Hale, E. C., Ball, M. B., Newman, N. S., Schibler,
631 K., Poindexter, B. B., Kennedy, K. A., Cotten, C. M., Watterberg, K. L., D'Angio, C. T., DeMauro,
632 S. B., Truog, W. E., Devaskar, U., Higgins, R. D., for the Eunice Kennedy Shriver National Institute of
633 Child Health, and Network, H. D. N. R. (2015). Trends in Care Practices, Morbidity, and Mortality
634 of Extremely Preterm Neonates, 1993-2012 Trends in Care, Morbidity, and Mortality of Extremely
635 Preterm Neonates Trends in Care, Morbidity, and Mortality of Extremely Preterm Neonates. *JAMA*,
636 314(10):1039–1051.
- 637 Tanaka, S., Kobayashi, T., Songjinda, P., Tateyama, A., Tsubouchi, M., Kiyohara, C., Shirakawa, T.,
638 Sonomoto, K., and Nakayama, J. (2009). Influence of antibiotic exposure in the early postnatal period
639 on the development of intestinal microbiota. *FEMS Immunology & Medical Microbiology*, 56(1):80–87.
- 640 Tang, W. W., Kitai, T., and Hazen, S. L. (2017). Gut microbiota in cardiovascular health and disease.
641 *Circulation research*, 120(7):1183–1196.
- 642 Tarr, P. I. and Warner, B. B. (2016). Gut bacteria and late-onset neonatal bloodstream infections in preterm
643 infants. In *Seminars in Fetal and Neonatal Medicine*, volume 21, pages 388–393. Elsevier.
- 644 Vatanen, T., Franzosa, E. A., Schwager, R., Tripathi, S., Arthur, T. D., Vehik, K., Lernmark, Å., Hagopian,
645 W. A., Rewers, M. J., She, J.-X., Toppari, J., Ziegler, A.-G., Akolkar, B., Krischer, J. P., Stewart, C. J.,
646 Ajami, N. J., Petrosino, J. F., Gevers, D., Lähdesmäki, H., Vlamakis, H., Huttenhower, C., and Xavier,
647 R. J. (2018). The human gut microbiome in early-onset type 1 diabetes from the teddy study. *Nature*,
648 562(7728):589.
- 649 Vatanen, T., Kostic, A., D'Hennessy, E., Siljander, H., Franzosa, E., Yassour, M., Kolde, R., Vlamakis, H.,
650 Arthur, T., and Hämäläinen, A. M. (2016). Variation in microbiome lps immunogenicity contributes to
651 autoimmunity in humans. *Cell*, 165(4):842–853.
- 652 Vogelzang, A., Guerrini, M. M., Minato, N., and Fagarasan, S. (2018). Microbiota—an amplifier of
653 autoimmunity. *Current opinion in immunology*, 55:15–21.
- 654 Wang, Q., Garrity, G. M., Tiedje, J. M., and Cole, J. R. (2007). Naive bayesian classifier for rapid
655 assignment of rna sequences into the new bacterial taxonomy. *Applied and environmental microbiology*,
656 73(16):5261–5267.
- 657 Wang, R., Xiao, Y., Lv, F., Hu, L., Wei, L., Yuan, Z., and Lin, H. (2018). Bacterial community structure
658 and functional potential of rhizosphere soils as influenced by nitrogen addition and bacterial wilt disease
659 under continuous sesame cropping. *Applied Soil Ecology*, 125:117–127.
- 660 Warner, B. B., Deych, E., Zhou, Y., Hall-Moore, C., Weinstock, G. M., Sodergren, E., Shaikh, N.,
661 Hoffmann, J. A., Linneman, L. A., Hamvas, A., Khanna, G., Rouggy-Nickless, L. C., Ndao, I. M.,
662 Shands, B. A., Escobedo, M., Sullivan, J. E., Radmacher, P. G., Shannon, W. D., and Tarr, P. I. (2016).
663 Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: A prospective
664 case-control study. *The Lancet*, 387(10031):1928–1936.
- 665 Wickham, H. (2016). *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York.
- 666 Winer, D. A., Luck, H., Tsai, S., and Winer, S. (2016). The intestinal immune system in obesity and
667 insulin resistance. *Cell metabolism*, 23(3):413–426.
- 668 Xiao, N. (2018). *ggsci: Scientific Journal and Sci-Fi Themed Color Palettes for 'ggplot2'*. R package
669 version 2.9.
- 670 Yatsunenkov, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris,
671 M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., Heath, A. C., Warner, B., Reeder, J., Kuczynski, J.,
672 Caporaso, J. G., Lozupone, C. A., Lauber, C., Clemente, J. C., Knights, D., Knight, R., and Gordon,
673 J. I. (2012). Human gut microbiome viewed across age and geography. *nature*, 486(7402):222.
- 674 Zhou, Y., Chen, H., He, H., Du, Y., Hu, J., Li, Y., Li, Y., Zhou, Y., Wang, H., and Chen, Y. (2016).
675 Increased enterococcus faecalis infection is associated with clinically active crohn disease. *Medicine*,
676 95(39).
- 677 Zhou, Y., Shan, G., Sodergren, E., Weinstock, G., Walker, W. A., and Gregory, K. E. (2015). Longitudinal
678 analysis of the premature infant intestinal microbiome prior to necrotizing enterocolitis: a case-control
679 study. *PLoS one*, 10(3):e0118632.
- 680 Zmora, N., Suez, J., and Elinav, E. (2019). You are what you eat: diet, health and the gut microbiota.
681 *Nature Reviews Gastroenterology & Hepatology*, 16(1):35–56.
- 682 Zonnenberg, I., van Dijk-Lokkart, E., van den Dungen, F., Vermeulen, R., and van Weissenbruch, M.
683 (2019). Neurodevelopmental outcome at 2 years of age in preterm infants with late-onset sepsis.
684 *European journal of pediatrics*, pages 1–8.

Table 1 (on next page)

Demographics Comparison among NEC, LOS and Control groups.

There was no statistical differences in gestational age, birth weight, gender and age when diagnosed among NEC, LOS and Control group. The mean length of stay differs among the three groups, which is within our expectation because it takes longer time for NEC or LOS patients to recover.

1

2 **Table 1. Demographics of NEC, LOS and Control groups.**

3 There was no statistical differences in gestational age, birth weight, gender and age when
 4 diagnosed among NEC, LOS and Control group. The mean length of stay differs among the three
 5 groups, which is within our expectation because it takes longer time for NEC or LOS patients to
 6 recover.

7

	NEC (n=4)	LOS (n=3)	Control (n=17)	Statistical test	P-value
GAge (weeks)¹	29.25 (29-30)	30.00 (29-31)	30.94 (28-33)	Kruskal-Wallis test	0.074
BW (grams)²	1416.3 (773.4-2149.1)	1141.7 (633.4-1649.9)	1527.4 (1391.6-1663.1)	Kruskal-Wallis test	0.111
Gender³				Fisher's exact test	0.822
Female	3 (75%)	2(67%)	9 (53%)		
Male	1 (25%)	1 (33%)	8 (47%)		
Age when Diagnosed (days)⁴	16 (11-19)	12 (10-22)	/	Wilcoxon rank-sum test	0.629
Length of Stay⁵ (days)	54.3 (13.5-95.0)	60.0 (24.8-95.2)	32.9 (26.3-39.5)	Kruskal-Wallis test	0.046
Total Number of Samples	45	44	103	/	/

¹GAge: Gestational Age = mean (range);

² BW: Birth Weight = mean (95% CI);

³ Age when diagnosed = mean (range)

⁴ Gender = number (%);

⁵Length of Stay = mean (95% CI)

Figure 1(on next page)

Schematic of Study Design.

Longitudinal fecal samples were collected from birth to death or discharge from the preterm infants in the NICU. Bacterial diversity and compositions were then characterized. Image credit: All the icons are made by Freepik from www.flaticon.com







Figure 2(on next page)

Trend in microbiome richness (Sobs) over time.

Microbial richness trend in case and controls. (A) control group. (B) NEC group. (C) LOS group. Horizontal line shows median, box boundaries show 25th and 75th percentiles. Sobs index value of each sample is depicted as one dot. Indices are analyzed using the Kruskal-Wallis test followed by the Mann-Whitney U test in comparisons between two adjacent intervals.

A**B****C**

Time Interval




▣ early post partum
 ▣ late pre-onset
 ▣ middle disease
 ▣ post disease

▣ early pre-onset
 ▣ early disease
 ▣ late disease

Figure 3(on next page)

Post-partum microbiome evenness (Shannon diversity) trend in each group.

Shows microbial richness trend in stools from cases and controls. (A) control group. (B) NEC group. (C) LOS group. Horizontal line shows median, box boundaries show 25th and 75th percentiles. Shannon index value of each stool is depicted as one dot. $p = 0.004$ for NEC and $p = 0.010$ for LOS from early pre-onset to early disease (two way RM ANOVA) indicating significantly discordant trends in bacterial diversity preceding disease onset. p values between two adjacent intervals were calculated by the Mann-Whitney U test.

A**B****C**

Time Interval

▣ early post partum
 ▣ late pre-onset
 ▣ middle disease
 ▣ post disease

▣ early pre-onset
 ▣ early disease
 ▣ late disease

Figure 4(on next page)

Post-partum microbiome evenness (Shannon diversity) in each time-interval.

Shows microbial richness trend in stools from cases and controls ((A) control group. (B) NEC group. (C) LOS group. Horizontal line shows median, box boundaries show 25th and 75th percentiles. Shannon index value of each stool is depicted as one dot. p values among three groups were calculated by Kruskal-Wallis test. Comparisons between two groups were calculated by the Mann-Whitney test.




Figure 5(on next page)

Beta diversity of the NEC, LOS and the control groups over time.

Beta diversity of samples is depicted by principal coordinates analysis 'PCoA' plot showing unweighted UniFrac distance between samples. Each dot represents the microbiota of a single sample. Samples from the same group is represented by the same colors. Scatter plot shows principal coordinate 1 (PC1) versus principal coordinate 2 (PC2). Percentages shown are percentages of variation explained by the components. Samples that clustered closer together are considered to share a higher proportion of the phylogenetic tree and represented by a higher percentage in PC1.








A. early post partum**B. early pre-onset****C. late pre-onset****D. early disease****E. middle disease****F. late disease****G. post disease**

Figure 6 (on next page)

Alluvial diagrams showing temporal development of microbiome in NEC, LOS and the control groups.

Genus of relative abundance over 10% were depicted. (A) control group. (B) NEC group. (C) LOS group.

